• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    GlaxoSmithKline Pharmaceuticals Limited — Board Meeting, 09-02-2026: Outcome of Board Meeting

    09-02-2026 | 03:22 pm

    GlaxoSmithKline Pharma's board approved Q3 & 9M FY26 consolidated results. Q3 PAT soared to ₹295.62 Cr (EPS ₹17.45) on ₹1041.26 Cr revenue, boosted by a ₹17.98 Cr land sale. 9M PAT was ₹758.12 Cr from ₹2826.37 Cr revenue. Employee costs increased due to new labor codes.

    No comments yet. Be the first to comment!

    All announcements from GlaxoSmithKline Pharmaceuticals Limited